Science has freed more innocent people from prison than any legal reform in the last century. That is not a metaphor. That is a fact with a body count attached to it.
The number that should make every lawyer uncomfortable
According to the National Registry of Exonerations, 614 wrongly convicted people have been exonerated through DNA evidence since 1989. The average person in those cases served 14 years before science corrected what the legal system got wrong. I think about that number every time someone tells me the justice system is self-correcting.
The law did not free those people. A molecule did. And now, the same scientific revolution that gave us forensic DNA is accelerating into something far more powerful: gene editing tools that are beginning to reshape not just criminal justice, but medicine, regulation, and the very definition of what the law can demand from the human body.
What CRISPR actually does and why the law has no framework for it
Most people have heard the word CRISPR without understanding what it means in practice. Here is the short version: scientists use a guide RNA to bring a protein called Cas9 to a precise spot in the DNA, where it makes a cut, and then genetic material can be added, removed, or changed. It is faster, cheaper, and more accurate than anything that came before it.
The first FDA-approved CRISPR therapy, Casgevy, treats sickle cell disease by editing a patient's own blood stem cells outside the body and returning them. In clinical trials, 29 out of 30 patients were free of severe pain episodes for at least 12 consecutive months after treatment. That is not a promising result. That is a cure.
And yet the legal infrastructure around this technology is embarrassingly thin. Regulatory frameworks for biotechnology in the United States were last comprehensively reviewed in 1992. The science has moved through several generations since then. The law has not.
A new CRISPR that does not even cut DNA
The latest development makes the regulatory gap even more glaring. Scientists at UNSW Sydney have developed a form of CRISPR that turns genes back on without cutting DNA at all, by removing chemical tags that silence genes. This gentler approach could offer a safer path to treating sickle cell disease by reactivating a fetal blood gene.
Meanwhile, researchers at UC San Diego created a gene-drive-inspired CRISPR tool that spreads through bacterial communities and deletes antibiotic resistance genes. Projections suggest antibiotic-resistant superbugs could kill more than 10 million people per year by 2050. This tool could reverse that trajectory.
“Transformative breakthroughs often arise at the intersection of disciplines and from the courage to follow curiosity into unfamiliar territory.”
— Jennifer Doudna, Nobel Laureate and CRISPR co-developer, American Chemical Society Priestley Medal Address 2026
The access problem is where the law fails hardest
Here is the bad edge moment I promised: the science is brilliant and the law around access is broken. Casgevy costs millions of dollars per patient. Insurers are struggling to pay upfront for therapies that save money over 30 years. The treatment also requires specialist transplant centers, meaning geography determines who gets cured.
I remember reading about sickle cell disease as a law student and thinking: this is a condition that disproportionately affects Black Americans, has been underfunded for decades, and now the cure exists but only for those with the right zip code and insurance plan. That is not a science failure. That is a policy failure.
Some will argue that the market will eventually drive prices down, as it did with HIV antiretrovirals. I do not buy that argument for gene therapy. HIV drugs became affordable because of sustained legal pressure, international trade battles, and government intervention. The market alone did not do it. The same fight is coming for CRISPR therapies, and we should start it now rather than wait another decade.
DNA freed 614 people. The law still blocks thousands more.
Back to the courtroom. The good edge here is real and worth celebrating: the Innocence Project has participated in overturning 254 convictions through DNA-based exonerations, and in about 40 percent of those cases, law enforcement identified the actual perpetrator using the same DNA results. Science did not just free the innocent. It caught the guilty.
But here is what keeps me up at night: in some states, people who plead guilty are barred from accessing DNA testing even if they falsely confessed or were coerced. The science exists. The evidence may exist. The law simply refuses to let it speak.
Almost 70 percent of DNA exonerees are people of color. That is not a coincidence. It is a pattern that the law has tolerated for decades while science quietly built the tools to expose it.
The ethical line the law must draw before science draws it for us
There is a real concern worth taking seriously: editing human germline cells (eggs, sperm, embryos) is highly controversial and largely prohibited by regulators worldwide. The fear of a genetic upper class, of designer babies, of heritable edits that future generations never consented to, is not science fiction.
A Chinese scientist already crossed that line, edited embryos, and served three years in prison for it. The response was international outcry. But outcry is not a legal framework. As of 2014, about 40 countries discouraged or banned germline editing research, but there is still no unified international enforcement mechanism.
The FDA took a meaningful step in February 2026, releasing draft guidance on a framework for platform therapies that could allow a single clinical trial to be customized for each individual patient. That is smart policy. It is also overdue. The science has been running laps around the regulators for years.
Would you trust a legal system to govern a technology it does not understand? Because right now, that is exactly what we are doing. The scientists are moving. The lawyers need to catch up.